Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Domer

Orthopaedic Surgery Phoenix, AZ Medical Doctor

NPI 1710983143 CMS profile 214171

3033 N 44Th St Ste 100, Phoenix, AZ 85018

Open in the dashboard

General payments

$15,682

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Domer of Phoenix, AZ is reported in the CMS Open Payments database as having received $15,682 across 142 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,842 39
2024 General $5,998 35
2023 General $565 7
2022 General $1,905 14
2021 General $693 17
2020 General $358 8
2019 General $2,322 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Domer
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Michael Domer were reported at $3,842. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Michael Domer Orthopaedic Surgery median Middle half National median
2019 $2,322 $644 $140–$2,844 $163
2020 $358 $312 $75–$1,860 $114
2021 $693 $520 $117–$2,495 $132
2022 $1,905 $598 $128–$2,731 $149
2023 $565 $461 $128–$2,264 $160
2024 $5,998 $497 $134–$2,475 $164
2025 $3,842 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $6,936 42 payments
  2. Zimmer Biomet Holdings, Inc. $2,649 34 payments
  3. Encore Medical, LP $1,785 5 payments
  4. DePuy Synthes Sales Inc. $1,281 17 payments
  5. Merck Sharp & Dohme Corporation $1,125 1 payment
  6. Vericel Corporation $1,023 18 payments
  7. Smith+Nephew, Inc. $261 5 payments
  8. Medtronic, Inc. $185 2 payments
  9. Lima USA, Inc. $144 1 payment
  10. Medacta USA, Inc. $89 1 payment
  11. Other $204 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,733 118 payments
  2. Travel and Lodging $5,256 21 payments
  3. Honoraria $1,500 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,125 1 payment
  5. Education $67 1 payment
Products named General payments · program years 2019–2025
  1. MAKO $6,514 34 payments
  2. AEQUALIS $1,753 2 payments
  3. DJO Surgical TaperFill Hip System $1,637 3 payments
  4. DJO Surgical Empowr Knee System $1,500 1 payment
  5. WINREVAIR $1,125 1 payment
  6. Persona $960 7 payments
  7. Oxford $915 8 payments
  8. MACI $778 15 payments
  9. Velys $632 6 payments
  10. ATTUNE $392 4 payments
  11. Other $3,858 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

162

Median for Orthopedic Surgery: 203

Drug cost

$694

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 21 $259
Oxycodone Hcl Generic 28 $181
Meloxicam Generic 28 $134
Amoxicillin Generic 74 $98
Clindamycin Hcl Generic 11 $22

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$172,484

Of which drugs: $33,492

Medicare patients

403

Average age 75

Services billed

12,949

233 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Ischemic heart disease 24%
Diabetes 23%
Chronic kidney disease 21%
Depression 17%
Atrial fibrillation 16%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 29 54 $29,263
Injection, methylprednisolone acetate, 1 mg J1010 Office 111 11,160 $1,139
Injection, methylprednisolone acetate, 80 mg J1040 Office 40 49 $301

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WINREVAIR
  • Merck Sharp & Dohme Corporation $1,125
$1,125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record